Drugs / KL0011034
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07841626 | Nov 2026 → Sep 2027 expected | — | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07828470 | Oct → Nov 2026 expected | — | Hunan Kelun Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07710560 | Jul → Aug 2026 | chronic pain syndrome | Hunan Kelun Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07474545 | Mar 2026 → Dec 2027 expected | — | Hunan Kelun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL0011034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710560 ↗ |
| Route | Intravenous | “Intravenous injection, continuous infusion” NCT07828470 ↗ |